Bio-Path calls in Acorn to help with siRNA drug trial

By Gareth Macdonald

- Last updated on GMT

Related tags: Acute myeloid leukemia, Pharmacology, Clinical trial

Bio-Path Holdings has called in US CRO Acorn to provide a contract medical officer for a study of its candidate antisense cancer drug liposomal Grb-2.

Under the agreement, Bradley Somer will serve as Bio-Path’s Medical Officer and medical liaison for trials of liposomal Grb-2 in various forms of the disease including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Bio-Path CEO Peter Nielsen, said that: “As we prepare to enter a Phase I clinical trial for our lead liposomal antisense cancer drug, it is important that the company have access to service capabilities needed for the conduct of the trial​.”

Dr. Somer is an excellent fit to perform as Bio-Path’s Medical Officer in our Phase I clinical trial. His extensive experience in hematology and conduct of clinical trials in CML for large pharmaceutical companies will allow him to play a significant role in Bio-Path’s clinical trial.”

Bio-Path has the option of extending the deal to include more trial support, including project management, clinical data management, statistical analysis, medical and scientific writing as well as support services.

Liposomal delivery may be way forward for siRNA

Texan firm Bio-Path is developing leading edge, patented, liposomal drug delivery systems at the University of Texas. Anderson Cancer Center with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development.

Bio-Path’s technology distributes nucleic acid drugs systemically, throughout the human body, via intravenous infusion, and can be applied both to double stranded and single stranded nucleic acid compounds.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more